10026TYR-219-01-NCT04474470Open (affiliates only)A Phase 1/2 Study with Open-Label, Dose Escalation Phase Followed by Single-Arm Expansion at the Maximum Tolerated Dose to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of NT219 Injection alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced solid tumors and Head and Neck cancerTYR-219-01NCT04474470IndustryAdultTreatmentI/IIColon; Multiple - inactiveWeinberg, BenjaminLombardi Comprehensive Cancer CenterPhase I/SarcomaOncology GroupLombardi Comprehensive Cancer Center (LCCC); Oncology PFS2021R3.1 Build 22 <a href="https://advarra.com" target="_blank">© 2024 Advarra, Inc.</a>